Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Northwest Biotherapeutics (NWBO) Long-Term Debt Issuances (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 15 years of Long-Term Debt Issuances data on record, last reported at $2.0 million in Q2 2025.

  • For Q2 2025, Long-Term Debt Issuances changed N/A year-over-year to $2.0 million; the TTM value through Sep 2025 reached $9.0 million, down 25.0%, while the annual FY2024 figure was $14.0 million, 30.0% down from the prior year.
  • Long-Term Debt Issuances reached $2.0 million in Q2 2025 per NWBO's latest filing, down from $5.0 million in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $16.1 million in Q4 2021 and bottomed at $600000.0 in Q1 2022.
  • Average Long-Term Debt Issuances over 5 years is $5.5 million, with a median of $3.6 million recorded in 2021.
  • Peak YoY movement for Long-Term Debt Issuances: plummeted 94.0% in 2022, then skyrocketed 1566.67% in 2023.
  • A 5-year view of Long-Term Debt Issuances shows it stood at $16.1 million in 2021, then crashed by 68.93% to $5.0 million in 2022, then soared by 100.0% to $10.0 million in 2023, then tumbled by 80.0% to $2.0 million in 2024, then changed by 0.0% to $2.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Issuances were $2.0 million in Q2 2025, $5.0 million in Q1 2025, and $2.0 million in Q4 2024.